Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.

摘要: Nucleoside reverse transcriptase inhibitor (NRTI) and protease (PI)/ritonavir sparing regimens may be useful to some HIV-infected patients. Nevirapine (NVP) raltegravir (RAL) are both potent antiretrovirals with good long-term safety profiles. We retrospectively identified from our electronic database all patients HIV RNA 6 months on an NVP-containing regimen no prior exposure integrase strand transfer inhibitors who were switched RAL plus NVP. Data was collected for 36 or until discontinuation of NVP any reason. A total 39 (30 male) included in this analysis. Median duration antiretroviral therapy 14 years (IQR 10-17) median plasma HIV-1 RNA<50 copies/ml switch 50 22-96). Switched mainly a boosted PI (n=24) tenofovir disoproxil fumarate/emtricitabine (n=12). After switching, the percentages 87.2% (95% CI 76.7, 97.7) 82.1% 70.0, 94.1) at 12 months, respectively, intent-to-treat-exposed analysis, 97.1% 91.6, 100) 94.1% 86.2, 100), per-protocol All follow-up month 24 (n=22) (n=14) had copies/ml. One virological failure observed (related archived non-nucleoside resistance mutation). During follow-up, patient experienced Grade 3 4 adverse events. values serum creatinine lipids significantly improved after switch. In prolonged copies/ml, switching NVP-RAL combination maintained suppression throughout months. This deserves further evaluation unable tolerate NRTI PI/ritonavir agents.